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The terminal globular domain of the paramyxovirus hemagglutinin-neuraminidase (HN) glycoprotein spike
has a number of conserved residues that are predicted to form its neuraminidase (NA) active site, by analogy
to the influenza virus neuraminidase protein. We have performed a site-directed mutational analysis of the role
of these residues in the functional activity of the Newcastle disease virus (NDV) HN protein. Substitutions for
several of these residues result in a protein lacking both detectable NA and receptor recognition activity.
Contribution of NA activity, either exogenously or by coexpression with another HN protein, partially rescues
the receptor recognition activity of these proteins, indicating that the receptor recognition deficiencies of the
mutated HN proteins result from their lack of detectable NA activity. In addition to providing support for the
homology-based predictions for the structure of HN, these findings argue that (i) the HN residues that mediate
its NA activity are not critical to its attachment function and (ii) NA activity is required for the protein to
mediate binding to receptors.
The paramyxoviruses are enveloped, negative-stranded RNA
viruses, including human parainfluenza viruses types 1 to 4,
mumps virus, and the animal pathogens Newcastle disease
virus (NDV), Sendai virus, and simian virus 5. The hemagglu-
tinin-neuraminidase (HN) glycoprotein spike not only medi-
ates receptor recognition but also possesses neuraminidase
(NA) activity, the ability to cleave a component of those re-
ceptors, sialic acid (35). The presence of both receptor recog-
nition and NA activities on the same protein is in contrast to
influenza virus, in which the two activities reside on indepen-
dent spike structures.
The HN spike is a type II homotetramer. The ectodomain
consists of a long stalk, supporting a terminal globular head, in
which reside the receptor recognition, NA, and antigenic sites
(26, 42). All HN tetramers are pairs of dimers. In the case of
the Australia-Victoria isolate of NDV (NDV-AV), the mono-
mers in each dimer are disulfide linked via a cysteine at posi-
tion 123 in the stalk region (26). NDV HN utilizes four of its
six potential glycosylation sites. Elimination of two of them, G1
and/or G2, results in an increase in hemadsorption (HAd)
activity (24).
Based on the conservation in HN of amino acids in the active
site of the influenza NA protein, the globular head of the HN
spike has been predicted to have a six b-sheet propeller struc-
tures, similar to the influenza virus protein; putative NA active-
site residues are contributed by five of the six b-sheets (5, 21).
This prediction is consistent with the antibody escape mutant
mapping of discontinuous epitopes on the NDV (17, 19), hu-
man parainfluenza virus type 3 (hPIV3) (4), and simian virus 5
(1) HN proteins.
In the influenza virus NA protein, residue D151 is thought to
be important to catalysis by virtue of its position within hydro-
gen-bonding distance of the glycosidic oxygen of the substrate
(2, 44). Several different substitutions for the corresponding
aspartic acid at position 198 in NDV HN abolish NA activity
(7), consistent with its having an analogous function in HN.
This prediction is consistent with the properties of monoclonal
antibodies (MAbs) to an antigenic site on NDV HN, called site
23. The binding of MAbs to this site can be blocked by a
competitive inhibitor of NA activity (18). The characterization
of antigenic variants has identified residues that flank D198 in
the linear amino acid sequence (F193, S194, S200, H201, and
H203) as contributing to antigenic site 23 (15, 18, 19, 23). In
addition, several substitutions in the site modulate NA and
attachment (15, 18). Finally, the NA activity of NDV-AV has
been shown to exhibit cooperativity, a phenomenon that is
eliminated in a site 23 variant carrying substitutions of F193L
and S200L (23). All of these data suggest that antigenic site 23
and the NA active site are closely linked and may be topolog-
ically overlapping.
The results of another mutational analysis are also consis-
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tent with the b-sheet propeller model. The longest linear
stretch of amino acids completely conserved among all HN
proteins is the NRKSCS sequence (residues 234 to 239 in NDV
HN). Jorgensen et al. (20) first predicted the close proximity of
this region to the NA site. Consistent with this, we have pre-
viously shown that substitutions for any of the first three resi-
dues in the sequence sharply diminish, although they do not
eliminate, NA activity (25).
We have now completed an extensive site-directed muta-
tional analysis of the role in NDV HN function of putative NA
active-site residues as predicted by homology with influenza
virus NA. Our findings are consistent with the homology-based
predictions for the structure of the NA active site in the
paramyxovirus HN protein. In addition, a total of seven resi-
dues have now been identified in the NDV HN protein for
which substitution results in a loss of detectable NA and re-
ceptor recognition activity. The receptor-binding activity of
these proteins can be partially restored by supplying NA activ-
ity either exogenously or by coexpression with another protein.
Furthermore, a mutant with less than 5% of wild-type NA
activity retains the ability to bind to receptors. These results
suggest that the receptor-binding activity of HN is dependent
on its NA activity and that less than 5% of the wild-type (wt)
amount of NA is sufficient for the protein to mediate receptor
recognition. The implications of this finding for the functional
and topological relationship between the NA and receptor
binding activities of HN are discussed.
MATERIALS AND METHODS
Recombinant plasmid vectors and site-directed mutagenesis. Construction of
the NDV-AV HN pBluescript SK(1) (Stratagene Cloning Systems, La Jolla,
Calif.) expression vectors and chimera CH1(111) has been described (8, 25).
Site-directed mutagenesis was performed as described previously (6), using
oligonucleotide primers obtained from Bio-Synthesis, Inc. (Lewisville, Tex.). The
presence of the desired mutation was verified by sequencing of double-stranded
DNA, using the Sequenase plasmid sequencing kit (United States Biochemical,
Cleveland, Ohio), according to protocols provided by the company. Multiple
clones were characterized for each substitution.
Transient-expression system and quantitation of cell surface HN. Wt and
mutant HN proteins were expressed in BHK-21 cells using the vaccinia virus-T7
RNA polymerase expression system (9). Maintenance of cells, infection with the
vaccinia virus recombinant, and transfection were performed as described (25),
except that 1 mg of each plasmid was used for transfection. Cell surface expres-
sion was quantitated by fluorescence-activated cell sorting (FACS) analysis, using
a mixture of MAbs to at least five different antigenic sites on the globular head
of HN (12, 13, 17, 19).
Functional assays. The HAd activity of HN proteins was determined by the
ability of the expressed protein to adsorb guinea pig erythrocytes (Crane Labo-
ratories, Syracuse, N.Y.). HN-expressing monolayers were incubated for 20 min
with a 2% suspension of erythrocytes in phosphate-buffered saline supplemented
with 1% CaCl2 and MgCl2. After extensive washing, adsorbed erythrocytes were
lysed in 50 mM NH4Cl, and the lysate was clarified by centrifugation. HAd
activity was quantitated by measuring the absorbance at 540 nm and subtracting
the background absorbance obtained with cells expressing the vector alone.
NA activity of cell surface HN was determined as described previously (25) on
duplicate monolayers incubated for 30 min at room temperature with 625 mg of
neuraminlactose (Sigma Chemical Co., St. Louis, Mo.) in 0.5 ml of 0.1 M sodium
acetate (pH 6). This buffer system was also used to measure NA activity at pH
5.5, while NA activities at pH 6.5 and 7 were determined using 0.1 M sodium
phosphate buffer.
Rescue of receptor-binding activity by NA activity. (i) NA supplied from an
exogenous source. Mutated HN proteins were expressed at the cell surface as
described above. The monolayer was washed with Dulbecco’s modified Eagle’s
medium (DMEM) (Life Technologies, Gaithersburg, Md.) and treated for 1 h at
37°C with DMEM containing 50 mU of Vibro cholerae NA (VCNA) (Sigma).
After extensive washing with DMEM, HAd activity was determined and quan-
titated as above.
(ii) NA supplied by a coexpressed protein. NA-deficient mutants lacking HAd
activity were coexpressed with an hPIV3-NDV HN chimera, CH1(111) (8). The
HAd activity of monolayers coexpressing the chimera and each mutant was
determined following treatment of the monolayer for 30 min at room tempera-
ture with 0.5 ml of DMEM containing an MAb that selectively inhibits the HAd
activity of the chimera. This treatment was previously shown to completely block
the HAd activity of monolayers coexpressing the chimera and wt HN. In this way,
the percentage of the total HAd that was mediated by the previously HAd-
deficient mutant could be determined.
Immunoprecipitation and SDS-PAGE. At 22 h posttransfection, BHK cells
were starved for 1 h at 37°C in DMEM without cystine and methionine, supple-
mented with 7% dialyzed fetal calf serum, nonessential amino acids, vitamins,
L-glutamine (2 mM), sodium bicarbonate (0.2%), penicillin, streptomycin, and
gentamicin. All medium components were obtained from Life Technologies.
Following starvation, the cells were labeled for 3 h at 37°C with 1 ml of medium
containing 100 mCi of Expre35S35S labeling mix (Dupont-New England Nuclear,
Boston, Mass.) per ml and chased with medium for 90 min. The cells were lysed,
and HN was immunoprecipitated and analyzed by sodium dodecyl sulfate-poly-
acylamide gel electrophoresis (SDS-PAGE) as described previously (26), except
that the antigen-antibody complexes were collected with Ultralink-Immobilized
Protein A Plus (Pierce, Rockford, Ill.). Digestion with peptidyl-N-glycosidase F
(PNGase F) was performed as described previously (6).
RESULTS
Mutation of predicted NA active-site residues. The align-
ment of NDV HN with the influenza virus NA active site
residues and six b-sheets is shown in Fig. 1, which has been
adapted from the Colman et al. (5) model. By analogy, the NA
site in HN is predicted to be formed by residues in five of the
six b-sheets, all except b3. In NDV HN, these include R174,
P176, and D198 (sheet 1), R235 (near the beginning of sheet
2), E401 and R416 (sheet 4), R449 (in the loop between the
fourth and fifth sheets), R498 (sheet 5), and Y526 and E547
FIG. 1. Alignment of residues in the globular domain of NDV HN with the six b-sheets and NA active-site residues on the influenza virus NA
protein. The numbers at the ends of each box are the first and last residues in each sheet. The residues in each sequence joined by lines are the
NA active-site residues in influenza virus NA and the corresponding putative NA active-site residues in HN.
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(sheet 6). In a number of instances, the putative NA active-site
residues localize to a domain that is highly conserved among
paramyxovirus HN proteins. These include the domains 174-
RIPS-177, 234-NRKSCS-239, 399-GAEGR-403, and 498-RX-
NPT/V-502.
With the goal of establishing the role of each of the above
residues in HN function, proteins carrying the following sub-
stitutions for a conserved residue in one of the above regions
of the protein were constructed: R174L, I175E, P176L, S177A,
K236R, R416L, R449L, R498L, N500D, V502A, Y526L, and
E547Q. The conserved domain 399-GAEGR-403 was not in-
cluded in this analysis, since a previous study (36) had shown
that substitutions for these residues either result in protein
misfolding (G399A, E401D, and R403K) or do not affect HN
function (A400G, G403A, and G403L).
We have previously shown that any of several substitutions
for residue D198 completely abolish NA activity (7), consistent
with its predicted role as the catalytic aspartic acid in the NA
active site (5). Also, previous mutational analyses revealed that
I175M and R235L substitutions result in a 12-fold and 15-fold
reduction in NA activity, respectively (25, 37).
Cell surface expression of mutated proteins. The cell surface
expression of each mutated protein was quantitated by FACS
analysis, using a panel of anti-HN MAbs specific for at least
five antigenic sites in the globular domain of the protein (Table
1). Of the mutated proteins that were detected at the cell
surface, those carrying R498L, N500D, or V502A substitutions
were expressed in amounts similar to that of the wt protein;
I175E, K236R, Y526L, and E547Q proteins were expressed 50
to 80% as efficiently as wt HN, and R174L and R416L mutated
HN were expressed at approximately 25% of the wt level. We
have previously shown that HN carrying any of several differ-
ent substitutions for D198 are expressed to at least 80% of the
wt HN level (7).
Proteins carrying P176L, S177A, or R449L substitutions
were not detectable at the cell surface. Since recognition of the
mutated proteins by the panel of anti-HN MAbs is highly
dependent on conformation, this strongly suggests that these
proteins are retained intracellularly in a misfolded form. In any
event, these proteins were not characterized further.
NA activity of mutated proteins. The NA activity of each of
the mutated proteins expressed at the cell surface was deter-
mined (Table 1). As shown previously for D198 HN (7), sub-
stitutions of R174L, I175E, K236R, R416L, Y526L, and
E547Q all result in a loss of detectable NA activity. NA activity
cannot be detected even after a threefold-longer incubation
period. On the other hand, three mutated proteins exhibit
detectable NA activity. Notably, all carry substitutions in the
putative NA-related conserved domain in b5. Proteins carrying
either the N500D or V502A substitution exhibit wt levels of
NA activity. R498L HN exhibits markedly reduced NA activity,
less than 5% of that of the wt protein. Though the three
mutated proteins that exhibit NA activity are also those that
are expressed at the surface at the highest levels, it seems
unlikely that the failure to detect NA activity with the other
expressed proteins is due solely to their relatively reduced cell
surface expression. We have demonstrated NA activity for
proteins expressed at as little as 25% of wt levels (25).
To determine whether any of the substitutions introduced
alter the pH optimum of the NA activity of the protein, the
activities of each mutated protein at pH 5.5, 6.5, and 7 were
compared to its activity at pH 6, the pH optimum of the wt
protein. These results are shown in Fig. 2 for proteins carrying
N500D and V502A substitutions. Other than the slightly
higher relative activity of V502A HN at pH 5.5, there is no
significant difference in the pH profiles of the two mutated
proteins and wt HN. All of the proteins that had no detectable
activity at pH 6 also failed to exhibit activity at the other pHs.
Similarly, the R498L HN also exhibited no change in its pH
optimum, with its low activity at pH 6 often reduced to mar-
ginally detectable levels at the other pHs (data not shown).
This suggests that the pH dependency of the protein is not
significantly altered by any of the substitutions.
FIG. 2. NA activity of wt, N500D, and V502A HN as a function of
pH. At 22 h posttransfection, the NA activity of the proteins expressed
at the cell surface was assayed as described previously (25). After
subtraction of the background absorbance obtained with the vector
alone, the data were expressed as a percentage of the activity at pH 6
for each protein, the optimum pH for wt NA activity. The data rep-
resent the averages of at least three independent experiments.
TABLE 1. Functional profile of putative NA active-site mutants
Amino acid
substitution b-Sheet
Avg cell surface
expressiona
(% of wt)
Avg NAb
(% of wt)
Avg HAdb
(% of wt)
R174L 1 21.0 6 8.9 — —
I175E 1 77.8 6 17.1 — —
D198Rc 1 89.8 6 5.0 — —
K236R 2 66.8 6 3.6 — —
R416L 4 27.4 6 6.4 — —
R498L 5 116.9 6 22.6 4.2 6 1.7 36.1 6 3.1
N500D 5 112.6 6 5.9 107.0 6 27.3 94.7 6 16.2
V502A 5 106.9 6 17.9 107.5 6 11.8 132.5 6 10.5
Y526L 6 51.5 6 13.9 — —
E547Q 6 80.0 6 16.1 — —
a Determined by FACS analysis and expressed as a percentage of wt HN. The
data are averages of three independent experiments.
b Expressed as a percentage of wt NDV HN. The data are averages of at least
three independent experiments. —, no activity detected.
c Taken from Deng et al. (7).
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HAd activity of mutated proteins. The receptor recognition
properties of the expressed, mutated proteins were evaluated
by assaying their ability to absorb guinea pig erythrocytes.
Without exception, all proteins that fail to exhibit detectable
NA activity also fail to exhibit detectable HAd activity (Table
1). Thus, loss of receptor recognition activity correlates com-
pletely with loss of NA activity.
The three mutants for which NA activity can be demon-
strated all exhibit HAd activity, with that of N500D HN being
comparable to wt activity. The V502A protein hemadsorbs
slightly more efficiently than wt HN. R498L HN hemadsorbs
about one third as well as the wt protein, perhaps related to its
markedly reduced NA activity.
NA and HAd deficiency correlate with an altered gel migra-
tion pattern. Figure 3 shows an SDS-PAGE analysis of the
electrophoretic migration pattern of each of the expressed, NA
active-site mutants compared to wt HN. Mutants R174L (lane
3), D198R (lane 5), K236R (lane 6), R416L (lane 7), Y526L
(lane 11), and E547Q (lane 12) all exhibit an altered gel mi-
gration pattern relative to the wt protein (lane 2). These mu-
tated proteins migrate as a distinct double band, one species
comigrating with wt HN and a second migrating as a slower-
moving, diffuse band. While this altered migration pattern cor-
relates with the lack of detectable NA and HAd activity for
these mutants, the migration rate and degree of diffuseness of
the slower-migrating band vary depending on the mutant. For
example, the defect, especially with respect to the retarded
migration rate of the slower-moving form, is most pronounced
for the D198R, K236R, and R416L proteins. It is less obvious
for the R174L, Y526L, and E547Q proteins.
A migration defect is barely detectable for the I175E pro-
tein. It does not exhibit a distinct slower-migrating form,
though it does migrate as a slightly more diffuse band than the
wt protein. Though it exhibits the same phenotype as the other
mutants, I175E HN is clearly a special case.
Each of the mutants for which NA and HAd are demonstra-
ble exhibits a gel migration pattern indistinguishable from that
of wt HN. These include the N500D and V502A proteins,
which have essentially wt NA and HAd activity, as well as
R498L HN, which has less than 5% of wt NA and approxi-
mately 36% of wt HAd activity.
Treatment with exogenous NA corrects the gel migration
defects of NA-HAd-deficient mutants. To determine whether
the gel migration anomalies exhibited by the NA active-site
mutants are based on differences in the structure of their
glycosyl groups, one mutant protein, D198R HN, was treated
with PNGase F. This enzyme cleaves the N-glycan linkage of
glycoproteins between asparagine and the carbohydrate chain
(41). As shown in Fig. 4, after treatment with this enzyme, both
wt HN and the D198R protein comigrate at a faster rate. This
confirms that the altered migration rate of this mutant is due
solely to glycosylation-based differences.
To begin to determine the relationship between the gel
migration defects in the NA active-site mutants and their lack
of NA activity, each radiolabeled protein was treated at the cell
surface with exogenously added VCNA. Immunoprecipitation
and SDS-PAGE confirm that the migrational defect is cor-
rected by this treatment; the NA-treated proteins all comigrate
with wt HN (Fig. 5A). This is consistent with the migration
defects, being due to differences in sialic acid content between
the mutants and wt HN.
Figure 5B compares the gel migration patterns of four of the
mutated proteins to that of wt HN both with and without
VCNA treatment. This allows us to compare the amount of
FIG. 3. SDS-PAGE analysis of immunoprecipitated NA active-site
mutants. At 22 h posttransfection, cells were starved, labeled, and
chased prior to lysis and immunoprecipitation with a mixture of HN-
specific MAbs. Cells express either vector (vec) alone (lane 1), wt NDV
HN (lane 2), or NDV HN carrying mutation R174L (lane 3), I175E
(lane 4), D198R (lane 5), K236R (lane 6), R416L (lane 7), R498L
(lane 8), N500D (lane 9), V502A (lane 10), Y526L (lane 11), or E547Q
(lane 12).
FIG. 4. PNGase treatment of wt and D198R HN. BHK cells were
transfected with either vector (vec, lanes 1 and 2), wt HN (lanes 3 and
4), or D198R HN (lanes 5 and 6). The cells were starved, labeled, and
lysed. The lysate from each well was split into two aliquots prior to
immunoprecipitation. The immunobeads with bound precipitates were
suspended in PNGase buffer (0.1 M sodium phosphate [pH 7.2], 25
mM EDTA) containing 0.8% SDS and boiled for 5 min. After cooling,
the solution was adjusted to contain 0.1% SDS and 0.5% NP-40. One
aliquot of each sample (lanes 2, 4, and 6) was digested with 200 mU of
PNGase F for 16 h at 37°C prior to SDS-PAGE.
FIG. 5. SDS-PAGE analysis of NA active-site mutants treated with
VCNA. (A) After starving, labeling, and chase as described for Fig. 3,
monolayers were treated for 1 h at 37°C with 50 mU of VCNA. After
extensive washing with DMEM, the cells were lysed and HN was
immunoprecipitated for display on SDS-PAGE. Samples are as fol-
lows: vector (vec, lane 1), wt NDV HN (lane 2), and NDV HN carrying
mutation R174L (lane 3), I175E (lane 4), D198R (lane 5), K236R
(lane 6), R416L (lane 7), R498L (lane 8), N500D (lane 9), V502A
(lane 10), Y526L (lane 11), or E547Q (lane 12). (B) Cells were trans-
fected as follows: wt HN (lanes 1 and 2), I175E HN (lanes 3 and 4),
D198R HN (lanes 5 and 6), K236R HN (lanes 7 and 8), or N500D HN
(lanes 9 and 10). The precipitating antibody is a mixture of HN-specific
MAbs. Samples were treated as in panel A (lanes 1) or left untreated
(lanes 2).
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sialic acid removed from each protein by the VCNA treatment.
As one might expect, the migration pattern of wt HN is unaf-
fected by the VCNA treatment (Fig. 5B, compare lanes 1 and
2); it has sufficient NA activity of its own. However, the slower-
migrating forms of HN proteins carrying D198R and K236R
substitutions are eliminated by treatment with VCNA (com-
pare lanes 5 and 6 and lanes 7 and 8, respectively). The gel also
again illustrates the marginal nature of the defect in I175E
HN. Its migration is made slightly less diffuse by the enzyme
treatment (compare lanes 3 and 4 in Fig. 5B), but the differ-
ence is certainly minor compared to mutants D198R and
K236R. As a control, the migration pattern of the N500D
protein is unaffected by the VCNA treatment, consistent with
its wt level of NA activity (compare lanes 9 and 10 in Fig. 5B).
Rescue of receptor recognition activity by treatment with
exogenous VCNA. We wondered whether the VCNA treat-
ment might also be capable of restoring receptor recognition
activity to the NA-HAd-deficient proteins. For these experi-
ments, we focused only on those NA-HAd-deficient mutants
that are expressed at the cell surface at least 50% as efficiently
as the wt protein, i.e., mutants carrying I175E, D198R, K236R,
Y526L, or E547Q substitutions (Table 1). The R174L and
R416L mutants were not tested, as they are expressed only
about 25% as well as wt HN.
Monolayers expressing the mutants were treated with exog-
enous VCNA, washed extensively to remove the enzyme, and
assayed for their ability to adsorb erythrocytes. Figure 6A
shows the amount of HAd activity exhibited by VCNA-treated
monolayers expressing each mutant relative to that of the wt
protein treated in the same way. VCNA treatment partially
rescued the HAd activity of each mutant. The percentage of wt
HAd activity varies from as little as 13.7% for D198R HN to as
much as 40.2% for E547Q HN. The conversion of these two
mutants from HAd deficient to HAd competent is shown in
Fig. 6B. These data indicate that an otherwise HAd-deficient
protein can be converted to a form competent to bind to
receptors by exogenous NA treatment.
Rescue of receptor recognition activity by coexpression with
another HN protein. Since NA treatment at the cell surface
could partially restore the HAd activity of the mutants, a series
of experiments were performed to determine whether the re-
ceptor recognition activity could be more efficiently rescued by
NA activity contributed by another coexpressed protein. The
HN protein chosen for these rescue assays was CH1(111), an
HN chimera in which the N-terminal 152 amino acid residues
are derived from hPIV3 HN and the C-terminal 435 amino
acids, including the entire putative globular domain, are de-
rived from NDV HN (8) (Fig. 7A). This protein has approxi-
mately 10% of the NA activity exhibited by wt NDV HN.
To distinguish the HAd activity of the mutant from that of
the chimera, an E347G mutation was introduced into each of
the NA-HAd-deficient mutant proteins (site 142). This muta-
tion was previously shown to have no detectable effect on the
receptor recognition, NA, or fusion properties of the virus but
renders it unrecognizable to MAbs specific for site 14 (16, 19)
(data not shown). MAbs to this site inhibit receptor recogni-
tion but not NA activity (12, 17, 18).
The HAd activity of monolayers coexpressing each 142 mu-
tant and the chimera was compared with that of monolayers
coexpressing wt HN lacking site 14 and the chimera, following
treatment with site 14 MAb (Fig. 7B). When any NA-HAd-
deficient mutant carrying the site 14 mutation is coexpressed
with the chimera, extensive HAd activity is observed in the
presence of the inhibiting antibody. Given the ability of the
MAb to inhibit the HAd activity of the rescuing chimera, any
HAd activity must be mediated by the previously receptor
recognition-deficient molecules. In each instance, the HAd
activities achieved in this system are greater than in the VCNA
rescue. The most significant increases in this assay over the
VCNA assay are for D198R HN (fourfold) and K236R HN
(twofold). In the coexpression assay, all mutants hemadsorb
between 40 and 60% of the wt-chimera control.
As additional controls, the HAd activity of wt HN and
CH1(111) coexpressing monolayers is completely blocked by
pretreatment with the antibody; the presence of the site 14
mutation does not affect the HAd-deficient phenotype of the
mutants; the site 14 MAb completely inhibits HAd activity of
monolayers coexpressing each mutant with the chimera, when
both retain the antigenic site; and antibody to site 1 that also
inhibits HAd but not NA recognizes HN carrying the site 14
substitution and completely inhibits the HAd activity of mono-
layers coexpressing the site 14 mutants and the chimera. Also,
we know that the chimera and NA-HAd-deficient proteins do
not form oligomers, since they have N termini derived from
heterologous HN proteins. This was verified by a sequential
immunoprecipitation and Western blot protocol (data not
shown). This means that the rescuing NA activity is not con-
tributed by monomers in the same spike.
Relationship between the NA active site and antigenic site
23. Based on our previous demonstration of the topological
proximity of antigenic site 23 and the NA active site (15, 18, 19,
23), we examined the ability of each of the NA active-site
mutants to be recognized by an antibody to site 23 by immu-
noprecipitation and SDS-PAGE (Fig. 8). HN carrying either
an R174L, D198R, or E547Q substitution is not immunopre-
cipitated by site 23 MAb, indicating that these residues con-
tribute to antigenic site 23. It is important to note that these
mutants are otherwise properly folded, as evidenced by their
recognition by the conformation-dependent panel of MAbs
used in the FACS analysis (Table 1) and the immunoprecipi-
tations shown in Fig. 3, 5A, and 5B.
Loss of receptor recognition activity is not due to alteration
in the structure of glycosyl groups. Rescue of the HAd activity
and correction of the migration defect of the NA-HAd-defi-
cient mutants by VCNA are reminiscent of a previous obser-
vation with the hemagglutinin of fowl plague virus, in which the
protein is rendered receptor binding deficient in the absence of
its NA protein (29). This suggests the possibility that the loss of
receptor recognition function by the NA-deficient HN mutants
might be due to failure to trim sialic acid from one or more
glycosyl moieties near the receptor-binding site on HN.
This possibility was tested for the NA-HAd-deficient pro-
teins carrying substitutions for D198 and I175. Each of the four
glycosylation sites that are used in HN was individually deleted
from the protein by the following amino acid substitutions: G1,
S121N; G2, T343N; G3, T435A; and G4, T483N. Since G1 and
G2 have been shown to be most closely associated with HN
function (24), mutants carrying deletions of both of these sites
were also constructed.
All of the glycosylation deletion mutants were expressed at
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the cell surface and had phenotypes indistinguishable from
those of the corresponding parent mutant, i.e., undetectable
NA and HAd activity (data not shown). These results indicate
that the lack of receptor recognition activity is not due to
interference by sialic acid residues on oligosaccharides near
the receptor-binding site. Thus, though the receptor recogni-
tion-deficient mutants exhibit alterations of carbohydrate
structure, their lack of attachment function is apparently un-
related.
DISCUSSION
Conserved residues in the paramyxovirus HN protein are
homologous to and can be aligned with functional and struc-
tural active-site residues conserved in all the influenza virus
NA proteins. On the basis of this homology, these HN residues
are predicted to constitute the functional and framework res-
idues of its NA active site, and the globular domain of the
protein is predicted to have a structural motif similar to that of
FIG. 6. Rescue of HAd activity of RR-deficient mutants by treat-
ment with VCNA. Monolayers were washed four times with DMEM
prior to incubation for 1 h at 37°C with 50 mU of VCNA. Following
four washes with DMEM, cells were assayed for HAd activity. (A)
HAd activity exhibited by each mutant following treatment at the cell
surface with VCNA. Data are expressed as a percentage of the HAd
activity exhibited by control wt HN monolayers treated in the same
way. Each value represents the average of at least nine determinations.
(B) HAd activity of untreated and VCNA-treated monolayers express-
ing D198R or E547Q HN. Untreated vector (vec)-expressing and
VCNA-treated HN-expressing monolayers are shown for reference,
though both are unaffected by the VCNA treatment.
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the influenza virus protein, i.e., a b-sheet propeller (5, 21).
With the goal of testing these predictions and isolating HN
proteins with altered NA activities, we have performed a site-
directed mutational analysis of the role in NDV HN function
of several of these invariant amino acids that are predicted to
constitute its NA active site.
Of the predicted NA active-site residues, substitutions for
five (R174, D198, R416, Y526, and E547) result in proteins
lacking detectable NA activity, and substitutions for two more
(R235 and R498) result in sharp reductions in NA (7, 25)
(Table 1). Thus, substitutions for all seven putative NA active-
site residues that allow cell surface expression of the protein
result in complete or nearly complete loss of NA activity. In
addition, substitutions for two other conserved residues, I175
and K236, whose relationship to the NA active site is not as
clear in the homology alignment (5, 21), also result in complete
loss of detectable NA activity (Table 1). Mutations at the
residues corresponding to I175 and D198 in several other HN
proteins also alter NA activity (11, 38, 45).
Thus, we have now shown that substitutions for a total of
seven residues predicted to be either part of the NA active site
or in close proximity to it completely abolish NA activity. This
strongly suggests that the homology-based model for the struc-
ture of the globular domain of HN is correct. As originally
proposed by Colman et al. (5), convergent evolution may have
taken place, resulting in a similar NA active-site structure in
influenza virus NA and the paramyxovirus HN protein, though
they have divergent polypeptide sequences.
All mutated HN proteins for which NA activity cannot be
demonstrated invariably also fail to mediate attachment to
receptors. The absence of NA activity correlates completely
with loss of detectable HAd activity. This speaks to the long-
standing question of the topological and functional relation-
ship between the NA and attachment sites on HN. The sim-
plest interpretation of this finding is that the NA active-site
substitutions also directly abolish attachment function and that
the NA site in HN also serves as the receptor-binding site.
However, this interpretation is inconsistent with out ability
to demonstrate that NA-HAd-deficient mutants can be ren-
dered HAd competent. When mutated proteins exhibiting this
phenotype are supplied with NA activity, their ability to bind
receptors is partially rescued. Thus, it seems unlikely that the
residues that mediate NA activity also directly mediate attach-
ment. Proteins carrying substitutions that abolish NA and HAd
activity can, in fact, be made competent for receptor recogni-
tion if supplied with NA activity. The lack of HAd activity is
secondary to and likely the result of the lack of NA. The more
effective rescue of HAd activity by the coexpressed protein,
compared with exogenous NA, is probably an indication that
the enzyme can act during intracellular transport.
A topological separation of the two activities is overwhelm-
ingly supported by an extensive body of evidence from MAb
functional inhibition studies (3, 10, 14, 17, 25, 27, 30, 32, 33)
and analyses of escape and temperature-sensitive mutants (31,
39, 40, 43). However, if the two sites are, indeed, topologically
distinct, this raises additional questions. First, if the NA active-
site residues do not directly mediate attachment, where in the
globular domain of the protein is the receptor-binding site?
Second, if different sites mediate the two activities, why are
FIG. 7. Rescue of HAd activity of RR-deficient mutants by coex-
pression with HN chimera CH1(111). (A) Structures of the RR-
deficient HN mutants and the rescuing chimera, CH1(111). Clear and
stippled areas are derived from NDV HN and hPIV3 HN, respectively.
Each RR-deficient mutant carries a substitution (E347G) that renders
it unrecognizable by antibody to site 14. In the CH1(111) chimera, the
N-terminal 152 amino acids are derived from hPIV3 HN and the
C-terminal 435 amino acids are derived from NDV HN. The chimera
exhibits approximately 10% of wt HN NA activity and is recognized by
the site 14 MAb. (B) HAd activity exhibited by each mutant carrying
the site 14 mutation coexpressed with chimera CH1(111) and treated
for 30 min at room temperature with 200 mg of site 14 MAb in 0.5 ml
of DMEM. Data are expressed as a percentage of the HAd activity of
wt HN carrying the site 14 mutation and treated in the same way. Each
bar represents the average of at least six determinations.
FIG. 8. SDS-PAGE analysis of immunoprecipitated NA active-site
mutants with MAb to antigenic site 23. After starvation, labeling, and
chase, HN was immunoprecipitated from lysates of labeled BHK cells
expressing vector (vec) alone (lane 1), wt NDV HN (lane 2), or NDV
HN carrying R174L (lane 3), I175E (lane 4), D198R (lane 5), K236R
(lane 6), R416L (lane 7), R498L (lane 8), N500D (lane 9), V502A
(lane 10), Y526L (lane 11), or E547Q (lane 12). The precipitating
antibody is HN23c, specific for antigenic site 23 on HN.
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they not functionally independent, i.e., why does loss of NA
also result in a loss of attachment function?
The first question can be approached by mapping epitopes
recognized by MAbs that differentially affect the two activities.
We have previously characterized MAbs to NDV HN that
block attachment but not NA with neuraminlactose as the
substrate (17). These antibodies have the potential to identify
an attachment-relevant domain on HN. They map to two over-
lapping sites (1 and 14) on the protein and select escape mu-
tants with substitutions for residues 345, 347, 350, and 353 at
the end of the large loop b3L23 in b-sheet 3 (19). These
residues are predicted to be quite distant from the NA active
site in the HN monomer (Fig. 9).
A role for b-sheet 3 in attachment was originally proposed
by Colman et al. (5) based on the lack of a structural counter-
part to it in the influenza virus NA protein and the fact that it
does not include any putative NA active-site residues (Fig. 1).
The structural model (21) suggests that this region is a large
loop domain which could fold relatively independently of the
rest of the protein. Our findings are consistent with the idea
that this region may be involved in attachment.
On the other hand, the conclusion that NA active-site resi-
dues are not directly involved in attachment can be questioned
in light of other evidence. We have previously shown that
mutants carrying I175M or I175V are HAd deficient, though
they have 8 and 21% of wt NA activity, respectively (37). This
is in contrast to I175E HN, shown here to be deficient for both
activities. These data, along with the difference in its migration
pattern compared to the other NA-deficient mutants, identifies
I175 as being unique among the putative NA active-site resi-
dues targeted in this study. This could be related to its pre-
dicted position as one of the first residues in the first strand in
b-sheet 1 in the HN globular domain (Fig. 1). Considering that
it is situated right under the important active-site residue
R174, I175 is probably very important to the structural integ-
rity of the active site. Interestingly, the properties of I175E HN
also suggest that the functional defects of the NA-HAd-defi-
cient mutants are not causally related to their gel migration
defects.
We have previously characterized MAbs to three overlap-
ping sites on HN, sites 2, 12, and 23, that block both NA
activity on neuraminlactose and attachment (17). This could be
interpreted to mean that the NA and HAd sites are the same.
Alternatively, the effect of these antibodies on attachment may
be indirect, i.e., due to their effect on NA. Relevant to this
point, all MAbs to NDV HN that inhibit NA also inhibit
attachment (14, 18, 28, 47). The same can be said for MAbs to
hPIV3 HN (3), though MAbs that inhibit NA but not attach-
ment have been described for Sendai virus (32). Also, changes
in NA activity have been known to affect attachment (15, 23).
While antibodies to overlapping sites 2, 12, and 23 on HN all
block NA activity, additional studies strongly suggest that site
23 is unique in that it may directly overlap the NA active site.
A low-molecular-weight competitive inhibitor of NA activity
can block the binding of MAbs to site 23 but not those to any
of the other sites (18). Previously identified site 23 residues at
positions 193, 194, 200, 201, and 203 (15, 18, 19, 23) are in close
proximity to residue D198, the putative catalytic aspartic acid
in the NA active site. The overlapping nature of antigenic site
23 and the NA active site is supported by the demonstration
that residue D198 contributes to the epitope recognized by a
site 23 MAb (Fig. 8). Furthermore, two other putative NA
active-site residues, R174 and E547, have now been identified
as part of site 23 (Fig. 8). Residue E547 was certainly not
obvious in this regard, as it is quite removed in the linear
amino acid sequence from the other known site 23 residues.
The overlapping nature of the NA active site and antigenic
site 23 is illustrated in Fig. 9, a RASMOL-generated depiction
of an HN monomer. Residues contributing to the NA active
site (green) and antigenic site 23 (magenta) are indicated.
Residues R174, D198, and E547, which map to both of these
sites, are labeled and colored yellow. As a reference, residues
between 350 and 353 in b-sheet 3, selected by MAbs that
inhibit only attachment but not NA on neuraminlactose, are
indicated in red. This figure illustrates the topology of the
overlap of the NA active site and site 23 and the separation of
the receptor recognition and NA activities of HN.
Whatever the structural relationship between the receptor
recognition and NA sites, it is clear that the two activities are
FIG. 9. NA active site and antigenic site 23 overlap. The RASMOL
molecular visualization program (34) was used to generate a model of
the globular domain of the NDV HN monomer. Residues (P176,
R235, E401, R416, R449, R498, and Y526) predicted to form the NA
active site are shown in green; residues (F193, S194, S200, H201, and
H203) at which substitutions have been identified in escape mutants
selected by MAbs to site 23 are shown in magenta; and residues (R174,
D198, and E547) that are part of both the NA site and site 23 are
shown in yellow as well as labeled. Residues (P345, E347, Y350, and
R353) at which substitutions have been identified in escape mutants
selected by MAbs to sites 1 and 14, which inhibit only HAd, are shown
in red. The interfaces with other monomers and the center of the
tetramer are indicated by lines and an asterisk, respectively.
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functionally intimately related; our data indicate that the
former is completely dependent on the latter. While one can-
not strictly rule out the possibility that any of the RR-deficient
mutants we have characterized has a small amount of NA
activity that is below the limit of detection in our assay, appar-
ently none of them has a sufficient level to render HN attach-
ment competent. What makes this study unique is that the
substitutions introduced are in conserved domains that all very
likely contribute to the structure of the NA active site. Previ-
ously, the relationship between NA and attachment had been
addressed through the analysis of antibody escape and tem-
perature-sensitive mutants that had altered activities. Only
when NA is reduced to an undetectable level does the depen-
dence of attachment on NA come into play. The threshold
level of NA sufficient for attachment function could conceiv-
ably be significantly less than 1% of the wt level (25).
It still remains to be determined why loss of NA also results
in loss of receptor-binding activity. The answer to this question
may be related to the long-standing notion that NA is first and
foremost a receptor-destroying activity. NA-minus mutants of
influenza virus have been described (22, 46). In characterizing
these mutants, Yang and Air (46) raised the issue of why
influenza viruses, as well as some paramyxoviruses and coro-
naviruses, need such an activity, unlike the vast majority of
other viruses. They postulated that a virus needs a receptor-
destroying activity only if its receptor can be incorporated into
the viral membrane along with the attachment protein. Ac-
cording to this hypothesis, the ability of NA-deficient NDV
HN to mediate attachment to receptors on the target cell
surface may be prevented by its association with receptors on
the surface of the transfected cell, an association it cannot
break due to its lack of receptor-destoying (NA) activity. Evi-
dently, NA contributed exogenously or by another coexpressed
protein can provide this activity and release HN to mediate
attachment. It will be informative to rescue the mutations
described here into an infectious clone of NDV to determine
the effect of NA deficiency on the life cycle of the virus.
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